Myeloproliferative Neoplasms (MPN)

Dr. Eileen Hu is an internal medicine specialist located in Dallas, TX, who completed her education at Ohio State University College of Medicine in 2022 and is currently undergoing her residency in internal medicine at the University of Texas Southwestern Medical Center, projected to finish in 2028. She has contributed to several publications focusing on leukemia, including works in Nature Genetics, Cell Reports, and Blood, with citations indicating engagement from the scientific community. Her research primarily revolves around acute myeloid leukemia, drug sensitivities, and cellular

Dr. Jamie Koprvinikar specializes in hematology and medical oncology and is board certified in both. She also holds a board certification in internal medicine. Dr. Koprivnikar received her medical degree from the Sidney Kimmel Medical College, formerly Jefferson Medical College of Thomas Jefferson University, in Philadelphia, PA. She completed her internal medicine residency at MedStar Georgetown University Medical Center in Washington, DC. She then completed a fellowship in hematology and oncology, also at MedStar Georgetown University Medical Center. She was chosen to serve as chief fellow

Clayton Jackson, M.D., is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center. He specializes in hematology and oncology. Dr. Jackson earned his medical degree at the Medical College of Georgia. He completed a residency in internal medicine and gained advanced training through a fellowship in hematology and oncology at Atrium Health Wake Forest Baptist Medical Center. He received advanced cellular therapy and bone marrow transplant training through a fellowship at Stanford Medical Center. Certified by the American Board of Internal Medicine in

Jan Philipp Bewersdorf, MD, specializes in hematology with a focus on the treatment of myeloid malignancies, including myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia.These conditions involve the abnormal development of blood cells and can present with symptoms such as fatigue, recurrent infections, and easy bruising. In his research, Dr. Bewersdorf collaborates with laboratory-based colleagues to integrate basic research with clinical applications, aiming to uncover new therapeutic strategies for diseases of the blood and bone marrow. "While we still cannot

I am a physician-scientist specializing in myeloproliferative neoplasms (MPN), bone marrow failure syndromes, lower risk myelodysplastic syndromes (MDS), and clonal hematopoiesis. I lead our MPN program, which was established in 2019 and provides clinical and research expertise for MPN patients. My research primarily focuses on mechanisms of thrombosis in MPN, with a goal to improve MPN care by individualizing thrombosis risk stratification and by finding better treatments to prevent thrombosis. I am also dedicated to training the next generation of physicians and am involved in medical

I am a physician-scientist who sees patients in clinic with disorders of clonal hematopoiesis and myeloid cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). My clinical and research interests focus on RNA regulation in hematologic malignancies. Specifically, I investigate how mutations in splicing factors affect RNA processing and contribute to disease progression. These genetic mutations can occur at any stage of life, leading to complex disorders that are often challenging to diagnose and treat. In the laboratory, we utilize advanced genomic technologies

Dr. Martinez is a physician-scientist who sees patients in clinic with disorders of clonal hematopoiesis and myeloid cancers, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Clinical and research interests focus on RNA regulation in hematologic malignancies. Specifically, he investigate how mutations in splicing factors affect RNA processing and contribute to disease progression. These genetic mutations can occur at any stage of life, leading to complex disorders that are often challenging to diagnose and treat. In the laboratory, he utilizes advanced genomic